Nexalis Therapeutics Ltd
Nexalis Therapeutics Ltd, formerly InhaleRx Limited, is an Australia-based clinical stage drug development company.
The business
Nexalis Therapeutics Ltd, formerly InhaleRx Limited, is an Australia-based clinical stage drug development company. The Company is focused on developing onset, inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The Company is focused on the development of IRX-211 to treat Breakthrough Cancer Pain (BTcP), and IRX-616a to treat panic disorders (PD) and SRX-25 for the treatment of Treatment-Resistant Depression (TRD). The Company operates through segment development of medicinal drug-device products to address unmet medical needs. Its IRX-211 focuses on the management of BTcP with non-opioid, onset inhaled therapy. The Phase I clinical trials for IRX-211 have been completed. Its IRX-616a is an approved inhaled medication for panic disorder, offering a novel treatment avenue.
Small Caps Research
No research on Nexalis Therapeutics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise NX1 based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.